Evoke Pharma Engages in Nationwide Gastroenterology Conference
Evoke Pharma Engages in Nationwide Gastroenterology Conference
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company dedicated to developing treatments for gastrointestinal (GI) diseases, has announced its participation in the Gastroenterology and Hepatology Advanced Practice Providers Conference. This significant event is set to take place over the course of three days at the Gaylord National Resort in National Harbor.
Matt D’Onofrio, the CEO of Evoke Pharma, expressed excitement about the company's continuous sponsorship of this pivotal conference, which focuses on nurse practitioners and physician assistants who significantly impact the management of patients struggling with GI disorders. D’Onofrio noted, "This gathering not only allows us to connect with advanced practice providers but also enables meaningful discussions regarding GIMOTI and its role in improving the lives of patients with diabetic gastroparesis. We are eager to engage with this community and share insights on our specialized treatment approaches."
At the conference, Evoke Pharma's management team, along with its commercial representatives, will host a booth aimed at fostering interactions and discussions with attendees. This immersive engagement will help healthcare providers understand the innovative solutions Evoke offers.
Understanding Gastroparesis and the Role of GIMOTI
Demittre Sorenson, a physician assistant at the Center for Advanced GI, emphasized the importance of GIMOTI in managing gastroparesis. Sorenson shared, "Through my extensive experience with GI patients, I often witness the struggles of those afflicted by gastroparesis. GIMOTI's nasal delivery system presents a promising alternative that can yield better outcomes compared to traditional oral medications. It provides much-needed relief, especially when symptoms are heightened, as it does not depend on the stomach's ability to process medication effectively."
This assertion signifies the potential of GIMOTI to significantly enhance the quality of life for patients dealing with this challenging condition, which affects millions globally.
About the Gastroenterology and Hepatology Advanced Practice Providers
The GHAPP organization is committed to advancing the professional development and education of advanced practice providers dedicated to the management of GI disorders. This annual conference represents an essential forum for healthcare professionals, focusing on the unique needs and challenges they face in their practice.
As the only national conference tailored specifically for APs in gastroenterology, it facilitates a deeper understanding of innovative treatments and the opportunity to share best practices among peers.
Innovative Treatments at the Forefront
Evoke Pharma has carved a niche in the pharmaceutical landscape through its focus on developing specialized medications for GI disorders. Among their key products is GIMOTI, which is specifically formulated to treat diabetic gastroparesis in adults. This condition inhibits the stomach from emptying its contents effectively, leading to various severe complications.
Before the introduction of GIMOTI to market, metoclopramide was only available as an oral or injectable drug, limiting options for patients. Now, GIMOTI provides an essential alternative, being the only FDA-approved treatment for gastroparesis currently available in the United States.
Learn More About Evoke Pharma
Individuals seeking more information on Evoke Pharma's innovative offerings and updates can visit their official website. The commitment to advancing GI treatment remains a cornerstone of the company’s mission, as they strive to meet the growing needs of patients and healthcare providers alike.
Frequently Asked Questions
What is Evoke Pharma focusing on during the GHAPP conference?
Evoke Pharma is focused on engaging healthcare providers and discussing their innovative treatment GIMOTI, particularly its effectiveness for diabetic gastroparesis.
What is GIMOTI?
GIMOTI is a nasal spray formulation of metoclopramide designed to relieve symptoms associated with acute and recurrent diabetic gastroparesis in adults.
What is the role of the GHAPP organization?
The GHAPP organization aims to provide education, resources, and professional advancement opportunities for advanced practice providers specializing in gastroenterology.
Why is the GHAPP conference important for advanced practice providers?
The conference is specifically designed to address the educational needs of providers who deal with GI disorders, offering them insights and peer discussions on best practices.
How can patients benefit from GIMOTI?
Patients benefit from GIMOTI as it offers an effective treatment option that does not rely on the stomach's ability to absorb medications, significantly improving their treatment experience.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.